Mesothelioma.com Resources for Patients and their Families

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Brief Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from a patient's tumor tissue may make the body build an immune response to kill tumor cells. Chemotherapy combined with vaccine therapy may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide with tumor cell vaccine in treating patients who have metastatic cancer or cancer at high risk of recurrence.

Tracking Information
First Received DateNovember 1, 1999
Last Changed DateJuly 9, 2013
Start DateApril 1991
Actual Primary Completion DateDecember 2007
Primary Outcome Measures

Clinical response (patients with evaluable disease)

Duration of response (patients with evaluable disease)

Survival (patients with evaluable disease)

Time to recurrence (patients without evaluable disease)

Survival (patients without evaluable disease)

Descriptive Information
PhasePhase 2
Study TypeInterventional
Condition
  • Breast Cancer
  • Colorectal Cancer
  • Kidney Cancer
  • Lung Cancer
  • Malignant Mesothelioma
  • Pancreatic Cancer
Intervention
  • Biological: allogeneic tumor cell vaccine
  • Biological: autologous tumor cell vaccine
  • Biological: recombinant interferon alfa
  • Biological: recombinant interferon gamma
  • Biological: sargramostim
  • Drug: cyclophosphamide
Study Arms / Comparison Groups1 / 0
Detailed Description

OBJECTIVES:

- Determine the safety and clinical effects of autologous or allogeneic active-specific intralymphatic immunotherapy with a vaccine containing interferon alfa or interferon gamma-treated tumor cells followed by sargramostim (GM-CSF) in patients with advanced cancer.

OUTLINE: This is a pilot study. Patients are stratified by tumor type.

Tumor tissue is removed from the patient and incubated with interferon alfa or interferon gamma for 72-96 hours. (If autologous tumor cells are not available, an allogeneic vaccine is prepared.) Harvested activated cells are irradiated immediately prior to use.

Patients receive cyclophosphamide IV. 48-72 hours after cyclophosphamide administration, patients receive tumor cell vaccine intradermally. Patients also receive sargramostim (GM-CSF) subcutaneously prior to vaccine administration and once daily for the next 8 days. Treatment repeats every 2 weeks for 3 courses in the absence of unacceptable toxicity. Patients with responding or stable disease after completion of course 3 may receive additional courses.

Patients are followed for survival.

PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 18-24 months.

Recruitment Information
Recruitment StatusCompleted
Anticipated Enrollment40
GenderAll
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed cancer not amenable to cure or long-term control by surgery, radiotherapy, chemotherapy, or hormonal manipulations, including the following tumor types:

- Colon cancer

- Lung cancer

- Renal cancer

- Breast cancer

- Pancreatic cancer

- Metastatic disease or subclinical disease at high risk of recurrence

- No brain metastases unresponsive to irradiation or surgery

- Hormone receptor status:

- Not specified

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Sex:

- Not specified

Menopausal status:

- Not specified

Performance status:

- ECOG 0-2 OR

- Karnofsky 70-100%

Life expectancy:

- At least 3 months

Hematopoietic:

- Not specified

Hepatic:

- Not specified

Renal:

- Not specified

Cardiovascular:

- No prior or concurrent significant cardiovascular disease

Pulmonary:

- No prior or concurrent pulmonary disease

Other:

- No prior or concurrent autoimmune disease

- No other prior or concurrent major medical illness

- HIV negative

- No clinical evidence of AIDS

- Not pregnant

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- See Disease Characteristics

- At least 4 weeks since prior chemotherapy

Endocrine therapy:

- See Disease Characteristics

- At least 4 weeks since prior hormonal therapy

- No concurrent chronic steroid therapy

Radiotherapy:

- See Disease Characteristics

- At least 4 weeks since prior radiotherapy

Surgery:

- See Disease Characteristics

Administrative Information
NCTIDNCT00002475
Responsible PartyCharles L. Wiseman,
SponsorSt. Vincent Medical Center - Los Angeles
Verification DateNovember 2008
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

Catching the Criminals: Mesothelioma Victim Frank Bender’s Legacy

Scientists Discover Possible Genetic Link for Mesothelioma in Young Adults

Medical Marijuana for Cancer: What to Know

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: